The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis.
 
Vikas Gupta
Honoraria - Novartis
Consulting or Advisory Role - Incyte; Novartis
Research Funding - Incyte; Novartis
 
Maria R. Baer
No Relationships to Disclose
 
Stephen T. Oh
Consulting or Advisory Role - Gilead Sciences; Incyte
Speakers' Bureau - Incyte
 
Carole Brennan Miller
Consulting or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences (Inst)
 
Susie Jun
Employment - Gilead Sciences; Gilead Sciences (I)
Stock and Other Ownership Interests - Gilead Sciences; Gilead Sciences (I)
Travel, Accommodations, Expenses - Gilead Sciences; Gilead Sciences (I)
 
Peter Lee
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Hua Dong
Employment - Gilead Sciences; Gilead Sciences (I)
Stock and Other Ownership Interests - Gilead Sciences; Gilead Sciences (I)
Research Funding - Gilead Sciences; Gilead Sciences (I)
Travel, Accommodations, Expenses - Gilead Sciences; Gilead Sciences (I)
Other Relationship - Gilead Sciences; Gilead Sciences (I)
 
Andreas Reiter
Honoraria - Novartis
Consulting or Advisory Role - Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis